Trial Profile
A randomised phase IIb trial of bevacizumab added to temozolomide ± irinotecan for children with refractory/relapsed neuroblastoma – BEACON-Neuroblastoma Trial
Status:
Active, no longer recruiting
Phase of Trial:
Phase II
Latest Information Update: 10 Jan 2024
Price :
$35
*
At a glance
- Drugs Bevacizumab (Primary) ; Dinutuximab beta (Primary) ; Cyclophosphamide; Irinotecan; Temozolomide; Topotecan
- Indications Neuroblastoma
- Focus Therapeutic Use
- Acronyms BEACON; BEACON-Immuno; BEACON-Neuroblastoma Trial; ITCC-SIOPEN BEACON
- 08 Jan 2024 Primary endpoint has not been met. (Best response (Complete Response or Partial Response) while on trial treatment, within 18 or 24 weeks depending on the arm of the trial participant is randomised to), as per Results published in the Journal of Clinical Oncology
- 08 Jan 2024 Results published in the Journal of Clinical Oncology
- 11 Aug 2022 This trial has completed in Austria as per the European Clinical Trials Database record.